StockData
Pfizer Inc logo

Pfizer Inc (PFE) KPIs and segments

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3048% above fair value
$28.47−0.39 (-1.35%)

Close on Nov 17, 2026Market cap $162.27BP/E 37.5Yield 6.04%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Pfizer · năm tài chính kết thúc December 31 (international subsidiaries generally report interim quarters on a one-month lag; FY2025 ended December 31, 2025; Q2 2026 ended June 28, 2026)

Nhìn nhanh KPI của Pfizer: 81 chỉ số vận hành, trong đó có Total R&D Pipeline Programs, Patients Treated Worldwide và U.S. Portfolio Average Net Price Change YoY, lấy từ 156 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Product($M)
11,86311,71514,49513,92011,95411,29415,08515,41710,87112,44312,33911,587
Royalty($M)
474396480436426308431384345263321260
Pfizer CentreOne($M)
373289409344348273326285278258
Pfizer Ignite($M)
40201726251517
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1
United States($M)
8,8578,7319,11910,6918,8948,3749,22112,0647,8929,5144,9128,064
International Developed Markets($M)
3,7433,4265,9213,6963,3933,1786,2833,4123,1643,1987,8163,335
International Emerging Markets($M)
2,4342,2932,5172,2672,3662,1632,2592,2262,2272,1671,8422,092
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)3
Kỳ báo cáo trước đây (báo cáo lần cuối 2026)4
Kỳ báo cáo trước đây (báo cáo lần cuối 2026)1
Remaining performance obligations (RPO)($M)
9,000
Total R&D Pipeline Programs (Phase 1 through Registration)12
9596102101108
Registration programs
25244
Phase 3 clinical programs
2525303030
Phase 2 clinical programs
3735383746
Phase 1 clinical programs
3131323028
New Molecular Entities (NMEs) in pipeline
56576159
Additional Indications in pipeline
39394142
Programs advanced or new since prior quarter
12101511
Programs discontinued since prior quarter
77911
Oncology — Total programs in pipeline4
56515657
Inflammation & Immunology — Total programs in pipeline4
18212224
Internal Medicine — Total programs in pipeline4
11141410
Vaccines — Total programs in pipeline4
10101010
Consolidated Operational Revenue Growth Excluding Comirnaty & Paxlovid YoY (%)(%)1
5.0%7.0%9.0%4.0%11.0%14.0%14.0%11.0%8.0%10.0%
Foreign Exchange (FX) Impact on Consolidated Revenues YoY ($M)($M)
21743127820322-25662-133-170-107
Full-Year Revenue Guidance — Lower end ($M)($M)8
60,50059,50061,00061,00061,00061,00059,80061,00059,50058,50058,00058,000
Deferred Revenue / Contract Liabilities — Government COVID-19 supply agreements ($M)($M)4
1,4001,5001,5001,8001,9001,9002,2003,5004,3004,1005,100
Government COVID-19 contract liabilities — Current ($M)($M)
5216466897901,0009321,4002,0002,5002,4002,600
Government COVID-19 contract liabilities — Noncurrent ($M)($M)
8558168261,0009069777851,5001,8001,6002,500
Remaining Performance Obligations (RPO) — Comirnaty multi-year contracts ($M)($M)
2,0002,1002,1003,0004,0003,0004,0006,0006,0006,0006,000
Remaining Performance Obligations (RPO) — Paxlovid multi-year contracts ($M)($M)
9659481,0001,0001,0001,0001,0001,0002,0002,0003,400
Eliquis (apixaban — BMS alliance & direct sales) — Worldwide revenues ($M)($M)4
2,4252,1662,0202,0152,0031,9231,8321,6171,8772,0401,6121,498
Eliquis (apixaban — BMS alliance & direct sales) — U.S. revenues ($M)($M)1
1,6511,4351,2351,2921,3221,2991,1261,0021,2621,413931883
Eliquis (apixaban — BMS alliance & direct sales) — International revenues ($M)($M)2
773731785723681624705616615626681615
Eliquis (apixaban — BMS alliance & direct sales) — Worldwide reported YoY (%)(%)
21.0%13.0%10.0%25.0%7.0%-6.0%14.0%8.0%7.0%9.0%9.0%2.0%
Eliquis (apixaban — BMS alliance & direct sales) — Worldwide operational (constant-currency) YoY (%)(%)
19.0%8.0%8.0%22.0%6.0%-4.0%13.0%9.0%8.0%10.0%9.0%3.0%
Prevnar Family (Prevnar 20 / Apexxnar & Prevnar 13 pneumococcal vaccines) — Worldwide revenues ($M)($M)4
1,3371,6901,7081,7421,3831,6601,5581,8031,3591,6911,6241,843
Prevnar Family (Prevnar 20 / Apexxnar & Prevnar 13 pneumococcal vaccines) — U.S. revenues ($M)($M)1
7481,0539661,1558601,1709441,3088321,1491,0121,299
Prevnar Family (Prevnar 20 / Apexxnar & Prevnar 13 pneumococcal vaccines) — International revenues ($M)($M)2
589637742587523491614495527542612544
Prevnar Family (Prevnar 20 / Apexxnar & Prevnar 13 pneumococcal vaccines) — Worldwide reported YoY (%)(%)
-3.0%2.0%10.0%-3.0%2.0%-2.0%-4.0%-2.0%-5.0%6.0%-8.0%15.0%
Prevnar Family (Prevnar 20 / Apexxnar & Prevnar 13 pneumococcal vaccines) — Worldwide operational (constant-currency) YoY (%)(%)
-4.0%-1.0%8.0%-4.0%2.0%-1.0%-4.0%-2.0%-4.0%7.0%-7.0%15.0%
Comirnaty (COVID-19 mRNA vaccine — BioNTech collaboration) — Worldwide revenues ($M)($M)4
2612322,2711,1513815653,3831,4221953545,3611,306
Paxlovid (nirmatrelvir/ritonavir oral COVID-19 treatment) — Worldwide revenues ($M)($M)4
211862181,2254274917272,7032512,035-3,135202
Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — Worldwide revenues ($M)($M)4
421353405412359248392337356178282233
Abrysvo (bivalent RSV vaccine — maternal & older adults) — Worldwide revenues ($M)($M)2
20818048127914313119835656145515375
FSME-IMMUN / TicoVac (tick-borne encephalitis vaccine) — Worldwide revenues ($M)($M)3
13281471001096334811003091
All Other Primary Care — Worldwide revenues ($M)($M)3
699654789721731609787742759770571670
Primary Care Portfolio Total [legacy pre-Q1 2026 realignment, through Q4 2025] ($M)($M)4
7,9387,6465,5405,6968,9119,0604,9527,2117,0446,310
Ibrance (palbociclib — HR+/HER2- metastatic breast cancer) — Worldwide revenues ($M)($M)3
1,0581,0081,0401,0571,0499771,0951,0871,1301,0541,1181,244
Ibrance (palbociclib — HR+/HER2- metastatic breast cancer) — U.S. revenues ($M)($M)1
707632686670696659713717741679712838
Ibrance (palbociclib — HR+/HER2- metastatic breast cancer) — International revenues ($M)($M)2
351376354387353318382371390375405406
Ibrance (palbociclib — HR+/HER2- metastatic breast cancer) — Worldwide reported YoY (%)(%)
1.0%3.0%-5.0%-3.0%-7.0%-7.0%-2.0%-13.0%-9.0%-8.0%-13.0%-3.0%
Xtandi (enzalutamide — alliance & royalty revenue with Astellas) — Worldwide revenues ($M)($M)3
534444592578566458565561495418457440
Xtandi (enzalutamide — alliance & royalty revenue with Astellas) — U.S. revenues ($M)($M)1
534444592578566458565561495418457440
Xtandi (enzalutamide — alliance & royalty revenue with Astellas) — Worldwide reported YoY (%)(%)
-6.0%-3.0%5.0%3.0%14.0%9.0%24.0%28.0%17.0%23.0%-2.0%-2.0%
Xtandi (enzalutamide — alliance & royalty revenue with Astellas) — Worldwide operational (constant-currency) YoY (%)(%)
-6.0%-3.0%5.0%3.0%14.0%9.0%24.0%28.0%17.0%23.0%-2.0%-2.0%
Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — Worldwide revenues ($M)($M)4
667591508464542426444409394341530
Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — U.S. revenues ($M)($M)1
64858550044953441943340738733453
Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — International revenues ($M)($M)
1978167711277
Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — Worldwide reported YoY (%)(%)
23.0%39.0%15.0%13.0%38.0%25.0%
Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — Worldwide operational (constant-currency) YoY (%)(%)
23.0%39.0%15.0%13.0%38.0%25.0%
Lorbrena / Lorviqua (lorlatinib — ALK+ NSCLC) — Worldwide revenues ($M)($M)4
354305282268251222192206169164146159
Adcetris (brentuximab vedotin ADC — lymphoma, via Seagen) — Worldwide revenues ($M)($M)4
196190220215255218285268279257560
Inlyta (axitinib — renal cell carcinoma) — Worldwide revenues ($M)($M)4
218214235226243219242247252237263252
Braftovi + Mektovi (encorafenib / binimetinib — BRAF+ melanoma/CRC/NSCLC) — Worldwide revenues ($M)($M)4
223174197202182136170173148116131131
Bosulif (bosutinib — CML) — Worldwide revenues ($M)($M)4
113129161150149151171161167145182160
Tukysa (tucatinib — HER2+ breast/colorectal cancer, via Seagen) — Worldwide revenues ($M)($M)4
138122119110132102129124121106180
Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — Worldwide revenues ($M)($M)1
14610913611297766457
Elrexfio (elranatamab — BCMA bispecific for multiple myeloma) — Worldwide revenues ($M)($M)4
898074858560574022136
Talzenna (talazoparib — PARP inhibitor) — Worldwide revenues ($M)($M)4
575049474640273632232220
Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — Worldwide revenues ($M)($M)3
3433323746333634332840
All Other Oncology — Worldwide revenues ($M)($M)3
338376303272394377286268347301411399
Oncology Portfolio Total [legacy incl. Oncology Biosimilars, through Q4 2025] ($M)($M)4
4,4354,2534,3873,7584,0644,0433,9563,5493,1893,115
Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac — ATTR-CM) — Worldwide revenues ($M)($M)4
1,7621,6021,6881,5911,6151,4861,5451,4471,3231,137961892
Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac — ATTR-CM) — U.S. revenues ($M)($M)1
1,064911910948990986975960861751534511
Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac — ATTR-CM) — International revenues ($M)($M)2
698691778643626499570486462386427381
Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac — ATTR-CM) — Worldwide reported YoY (%)(%)
9.0%8.0%9.0%10.0%22.0%31.0%61.0%62.0%69.0%66.0%41.0%48.0%
Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac — ATTR-CM) — Worldwide operational (constant-currency) YoY (%)(%)
8.0%4.0%7.0%7.0%21.0%33.0%60.0%63.0%71.0%66.0%39.0%47.0%
Xeljanz (tofacitinib — rheumatoid arthritis / ulcerative colitis) — Worldwide revenues ($M)($M)4
251180324313322128349321303194493503
Oncology Biosimilars Portfolio (Ruxience, Zirabev, Trazimera, Nivestym, Nyvepria) — Worldwide revenues ($M)($M)4
359409369315353264209285279264322310
Sulperazon (cefoperazone/sulbactam — hospital anti-infective) — Worldwide revenues ($M)($M)1
116199169154166164170156144167138122
Octagam / Panzyga (immunoglobulin portfolio) — Worldwide revenues ($M)($M)3
13812212011396881092211048153
Inflectra / Remsima (infliximab biosimilar) — Worldwide revenues ($M)($M)4
17118218117313915312712697158117121
Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — Worldwide revenues ($M)($M)3
199150181158163135159152150125133130
Enbrel (etanercept — international outside U.S./Canada) — Worldwide revenues ($M)($M)3
142138180154154140183169179159203208
Genotropin (somatropin — growth hormone) — Worldwide revenues ($M)($M)4
949311712810695112119119120160158
Zithromax (azithromycin) — Worldwide revenues ($M)($M)3
421121137356158122837420015260
Cibinqo (abrocitinib — atopic dermatitis) — Worldwide revenues ($M)($M)4
947678796958646347423737
All Other Specialty Care — Worldwide revenues ($M)($M)4
566579477407453486345323429513217202
Total Biopharma Alliance Revenues (cross-portfolio summary) — Worldwide revenues ($M)($M)4
2,6972,3392,5822,2982,2732,1132,2481,9002,0672,1721,9101,645
Total Biopharma Royalty Revenues (cross-portfolio summary) — Worldwide revenues ($M)($M)4
474396480436426308431384345263321260
Pfizer CentreOne (Contract Development & Manufacturing Organization — CDMO) — Worldwide revenues ($M)($M)4
373289409344348273325285278258364293
Specialty Care Portfolio Total [legacy pre-Q1 2026 realignment, through Q4 2025] ($M)($M)4
4,7714,4114,3783,9874,4384,2894,0833,8433,9533,763
U.S. Commercial Division Revenues [legacy 2024–2025 structure] ($M)($M)2
9,03110,5998,7938,2859,11411,9647,8289,42611,0705,864
Historical / Mature / Divested Brands [legacy disclosures] — Vyndaqel/Hospital/Upjohn history ($M)14
Total Gross-to-Net (GTN) Rebate, Chargeback & Return Accruals ($M)($M)4
12,12811,55011,66612,94011,66710,94510,82212,0979,4018,4819,0147,757
Accrued rebates — Medicaid, Medicare & commercial contracting (Current liabilities) ($M)($M)
9,2938,8467,9099,1578,6928,1197,1958,2526,7265,8805,5465,083
Allowance against trade accounts receivable — Chargebacks, discounts & returns ($M)($M)
1,7411,6991,8032,1481,5891,4621,6271,9551,5781,5731,7701,599
Noncurrent accrued rebates & revenue deductions (Other noncurrent liabilities) ($M)($M)
3322871,2041,0097424611,029822569382796640
Other current GTN accruals ($M)($M)
7637187506256449049721,068529646902436
ViiV Healthcare Limited (HIV Joint Venture, 11.7% Pfizer Stake) — Standalone Net Revenues ($M)1
ViiV Healthcare — Cash dividends paid to Pfizer ($M)($M)
988281727339894874615230
Acquisition Contingent Consideration Liabilities — Current fair value ($M)($M)1
96959539179
Restructuring Reserve Liability — Total ending balance ($M)($M)16
1,6821,5881,9101,8361,9862,3992,1202,1322,3991,6381,988585
Restructuring reserve — Current liability ($M)($M)
9721,2001,4001,3001,3001,8001,7001,1001,0001,1001,300447
Restructuring reserve — Noncurrent liability ($M)($M)
7104314665326855624371,1001,400519663137
Restructuring reserve — Employee termination / severance costs ($M)($M)
1,5751,4671,7831,6821,7882,1812,0462,1202,3701,6281,978573
Restructuring reserve — Exit & other restructuring activities ($M)($M)
107121127155198218741229101112
Enterprise Cost Realignment Program (2023–2027) — Cumulative costs incurred to date ($M)($M)
4,9004,3004,2003,7003,5003,2002,6001,8001,5001,6001,700
Cost Realignment Program — Cumulative costs attributable to Biopharma ($M)($M)
3,8003,3003,2002,9002,7002,7002,1001,4001,2001,300674
Cost Realignment Program — Total expected program one-time costs ($M)($M)
4,7004,7004,7004,7003,1003,100
Manufacturing Optimization Program — Cumulative Phase 1 costs incurred to date ($M)($M)
1,1001,1001,1001,2001,2001,3001,300
Manufacturing Optimization Program — Total expected Phase 1 costs ($M)($M)
1,4001,4001,4001,4001,4001,6001,6001,7001,700
Restructuring charges recognized in period — Total ($M)($M)
41949308237-746216562171,104101,80371
Restructuring charges — Employee termination costs ($M)($M)
35415324124-148384143251,013-291,54516
Restructuring-related asset impairments ($M)($M)
54282111144173255111412518240
Restructuring charges — Exit & other costs ($M)($M)
116-37230642588249147515
Restructuring reserve utilization / cash payments — Total ($M)($M)
324371235386339342669484343360400200
Restructuring reserve utilization — Severance payments ($M)($M)
247330223230245249216275272320140144
Acquisition integration & implementation costs ($M)($M)
653195815423546738083981,3641682,730276
Biopharma Operating Segment — Segment Pretax Income / Earnings ($M)($M)11
6,8876,8386,9138,4696,8917,0696,2628,2695,8977,6221,345-137
Non-GAAP Adjusted Income Attributable to Pfizer Common Shareholders ($M)($M)1
4,4404,2903,7864,9494,4345,2373,5926,0503,4004,674593-968
Non-GAAP Adjusted Diluted EPS ($/share)($)
0.770.750.660.870.780.920.631.060.600.820.10-0.17
Inventories — Work-in-process ($M)($M)4
5,1605,7135,6346,0386,5145,5536,1017,2677,0726,2735,6886,515
Inventories — Finished goods ($M)($M)
3,8874,0314,1134,4854,1264,1623,7753,2803,2203,4913,4952,892
Inventories — Raw materials & supplies ($M)($M)
8989239079451,0291,1379761,1741,1561,1281,007797
Noncurrent inventories (included in Other noncurrent assets) ($M)($M)
2,4192,4622,3702,1422,3602,7932,6632,7652,9183,3614,5681,416
Supplier Finance Program — Confirmed obligations outstanding ($M)($M)
545518574566501546688628593658791781
Finite-Lived Intangible Assets — Net carrying amount ($M)($M)7
29,27330,91831,51033,51334,02834,62235,84837,34038,59439,89940,11627,830
Property, Plant & Equipment — Gross carrying value ($M)2
U.S. Defined Benefit Pension Plans — Projected benefit obligation (PBO) ($M)3
U.S. Real Personal Consumption Expenditures — Pharmaceutical & Medical Products ($B SAAR)($M)
3,7903,7003,6673,6153,5303,4653,4183,3583,2883,2443,1593,079
DB Segment — Biopharma Segment Revenues ($M)($M)
14,66114,16117,14316,31014,30513,44117,41317,39212,99114,60414,18613,188
Consolidated Revenues ($M)($M)10
15,03414,45117,55716,65414,65313,71517,76317,70213,28314,87914,56913,491
Total Assets ($M)($M)9
201,131207,618208,160208,731206,095208,028213,396219,476216,193221,095226,501215,021
Operating Cash Flow ($M)($M)4
8352,6155,3484,603-5822,3356,7216,714-1,7811,0905,2403,456

152 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar & accounting basis: Pfizer Inc. operates on a calendar fiscal year ending December 31 in the U.S. (international operations are generally consolidated on a December–November fiscal year, with Q1–Q3 interim periods ending on the Sunday nearest March 31, June 30, and September 30; Q2 2026 ended June 28, 2026). Under US GAAP, Pfizer is exempt from parent-company-only Schedule I disclosures (restricted net assets of subsidiaries < 25% of consolidated net assets), so parent vs. subsidiary subtraction is not applicable.
  • Q1 2026 Biopharma portfolio realignment: Beginning Q1 2026, Pfizer reorganized Biopharma revenues from three categories (Primary Care, Specialty Care, Oncology) into four categories by carving out Global Hospital & Biosimilars (sterile injectables, anti-infectives, and Oncology/Specialty biosimilars) without restating Q4 2025. Per RULES.md Step 5, pre-2026 category totals are preserved as explicitly labeled legacy series through Q4 2025, while individual medicine/vaccine series remain continuous across all periods.
  • Core operational & commercial KPIs (Groups 1–9) cover: (1) R&D Pipeline snapshot (95 clinical programs at Q2 2026: 5 Registration, 27 Phase 3, 27 Phase 2, 36 Phase 1; 54 NMEs + 41 additional indications across Oncology, Inflammation & Immunology, Internal Medicine, and Vaccines), global patient reach (449M total / 335M ex-COVID patients treated in FY25), U.S. portfolio average net price change (-2% total / -5% ex-COVID in FY25), consolidated ex-COVID operational revenue growth (+5% in Q2 2026), full-year guidance ranges ($60.5B–$62.5B revenue and $2.80–$3.00 Adjusted Diluted EPS as of Q2 2026), and contracted Comirnaty/Paxlovid RPO & government COVID-19 contract liabilities ($2,756M at Q2 2026); (2–4) Worldwide, U.S., and International revenues plus reported & operational YoY % for 30+ active medicines/vaccines (led by Eliquis $2,099M, Prevnar family $1,422M, Vyndaqel family $1,796M, Ibrance $1,024M, Padcev $543M, Xtandi $594M, Nurtec ODT $407M in Q2 2026), Alliance/Royalty revenues, Pfizer CentreOne CDMO, and 20 historical LOE/Upjohn franchises; (5) Gross-to-Net rebate & chargeback balance-sheet reserves ($11,334M at Q2 2026 / $11,666M at FY25), Top-3 U.S. wholesaler concentration (McKesson 32%, Cencora 24%, Cardinal Health 14% of FY25 revenue; 82% of gross trade AR), and blockbuster breadth (12 products >$1B = 65% of FY25 Biopharma revenue); (6) Standalone summarized financials of ViiV Healthcare Limited (11.7% equity-method HIV JV: $9,517M revenue / $2,487M net income in FY25), collaborative profit-sharing flows, and M&A contingent consideration; (7) Enterprise Cost Realignment ($4,900M cumulative costs through Q2 2026) & Manufacturing Optimization ($1,100M cumulative costs), ASU 2023-07 Biopharma segment expense lines, and Non-GAAP Adjusted Income ($4,458M / $0.78 EPS in Q2 2026); (8–9) 36 global manufacturing sites, inventory stages, intangibles & 5-year amortization schedule, pension obligations/assets, unrecognized tax benefits, 75,000 global employees, CEO Pay Ratio (277:1 in FY25), Form 11-K U.S. ($24.20B net assets) & Puerto Rico Savings Plans, FDA inspections/recalls, safety (0.28 TIR), and Scope 1–3 GHG/water/waste.

Không hiện vì thiếu các kỳ gần đây (33)

  • Core Operational KPIs — R&D Pipeline, Patient Reach, Pricing, Guidance & Backlog › Consolidated Operational Revenue Growth Excluding Comirnaty & Paxlovid YoY (%) › Operational growth of recently launched & acquired products YoY (%)
  • Primary Care — Brand Revenues (Eliquis, Prevnar, Nurtec ODT, Vaccines & COVID-19) › Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — Worldwide revenues ($M) › Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — International revenues ($M) › Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — International reported YoY (%)
  • Primary Care — Brand Revenues (Eliquis, Prevnar, Nurtec ODT, Vaccines & COVID-19) › Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — Worldwide revenues ($M) › Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — International revenues ($M) › Nurtec ODT / Vydura (rimegepant — migraine, acquired via Biohaven) — International operational (constant-currency) YoY (%)
  • Primary Care — Brand Revenues (Eliquis, Prevnar, Nurtec ODT, Vaccines & COVID-19) › Abrysvo (bivalent RSV vaccine — maternal & older adults) — Worldwide revenues ($M) › Abrysvo (bivalent RSV vaccine — maternal & older adults) — International revenues ($M) › Abrysvo (bivalent RSV vaccine — maternal & older adults) — International reported YoY (%)
  • Primary Care — Brand Revenues (Eliquis, Prevnar, Nurtec ODT, Vaccines & COVID-19) › Abrysvo (bivalent RSV vaccine — maternal & older adults) — Worldwide revenues ($M) › Abrysvo (bivalent RSV vaccine — maternal & older adults) — International revenues ($M) › Abrysvo (bivalent RSV vaccine — maternal & older adults) — International operational (constant-currency) YoY (%)
  • Primary Care — Brand Revenues (Eliquis, Prevnar, Nurtec ODT, Vaccines & COVID-19) › Primary Care Portfolio (Q1 2026 realigned basis) — Worldwide ($M) › Primary Care Portfolio (Q1 2026 realigned basis) — U.S. ($M)
  • Primary Care — Brand Revenues (Eliquis, Prevnar, Nurtec ODT, Vaccines & COVID-19) › Primary Care Portfolio (Q1 2026 realigned basis) — Worldwide ($M) › Primary Care Portfolio (Q1 2026 realigned basis) — International ($M)
  • Primary Care — Brand Revenues (Eliquis, Prevnar, Nurtec ODT, Vaccines & COVID-19) › Primary Care Portfolio (Q1 2026 realigned basis) — Worldwide ($M)
  • Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — Worldwide revenues ($M) › Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — International revenues ($M) › Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — International reported YoY (%)
  • Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — Worldwide revenues ($M) › Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — International revenues ($M) › Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — International operational (constant-currency) YoY (%)
  • Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — Worldwide revenues ($M) › Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — U.S. revenues ($M) › Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — U.S. reported YoY (%)
  • Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — Worldwide revenues ($M) › Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — Worldwide reported YoY (%)
  • Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — Worldwide revenues ($M) › Orgovyx (relugolix — prostate cancer, Sumitomo collaboration) — Worldwide operational (constant-currency) YoY (%)
  • Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — Worldwide revenues ($M) › Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — U.S. revenues ($M) › Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — U.S. reported YoY (%)
  • Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — Worldwide revenues ($M) › Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — International revenues ($M) › Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — International reported YoY (%)
  • Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — Worldwide revenues ($M) › Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — International revenues ($M) › Tivdak (tisotumab vedotin ADC — cervical cancer, via Seagen) — International operational (constant-currency) YoY (%)
  • Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › All Other Oncology — Worldwide revenues ($M) › All Other Oncology — Worldwide reported YoY (%)
  • Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Oncology Portfolio (Q1 2026 realigned basis, excl. Oncology Biosimilars) — Worldwide ($M) › Oncology Portfolio (Q1 2026 realigned basis) — U.S. ($M)
  • Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Oncology Portfolio (Q1 2026 realigned basis, excl. Oncology Biosimilars) — Worldwide ($M) › Oncology Portfolio (Q1 2026 realigned basis) — International ($M)
  • Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies) › Oncology Portfolio (Q1 2026 realigned basis, excl. Oncology Biosimilars) — Worldwide ($M)
  • Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO › Sulperazon (cefoperazone/sulbactam — hospital anti-infective) — Worldwide revenues ($M) › Sulperazon (cefoperazone/sulbactam — hospital anti-infective) — U.S. revenues ($M) › Sulperazon (cefoperazone/sulbactam — hospital anti-infective) — U.S. reported YoY (%)
  • Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO › Sulperazon (cefoperazone/sulbactam — hospital anti-infective) — Worldwide revenues ($M) › Sulperazon (cefoperazone/sulbactam — hospital anti-infective) — U.S. revenues ($M)
  • Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO › Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — Worldwide revenues ($M) › Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — U.S. revenues ($M) › Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — U.S. reported YoY (%)
  • Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO › Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — Worldwide revenues ($M) › Zavicefta (ceftazidime/avibactam — Gram-negative anti-infective) — U.S. revenues ($M)
  • Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO › Enbrel (etanercept — international outside U.S./Canada) — Worldwide revenues ($M) › Enbrel (etanercept — international outside U.S./Canada) — U.S. revenues ($M) › Enbrel (etanercept — international outside U.S./Canada) — U.S. reported YoY (%)
  • Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO › Enbrel (etanercept — international outside U.S./Canada) — Worldwide revenues ($M) › Enbrel (etanercept — international outside U.S./Canada) — U.S. revenues ($M)
  • Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO › Zithromax (azithromycin) — Worldwide revenues ($M) › Zithromax (azithromycin) — U.S. revenues ($M)
  • Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO › Specialty Care Portfolio (Q1 2026 realigned basis) — Worldwide ($M)
  • Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO › Global Hospital & Biosimilars Portfolio (created Q1 2026) — Worldwide ($M)
  • Joint Venture (ViiV Healthcare), Collaborative Profit-Sharing & Contingent Consideration › Acquisition Contingent Consideration Liabilities — Current fair value ($M) › Fair value remeasurement of contingent consideration in P&L ($M)
  • Workforce, Form 11-K Savings Plans, Governance, FDA Quality & Environmental Impact › Supply Chain 3TG Conflict Minerals (Form SD) — Known smelters & refiners › Form SD — RMAP-conformant 3TG smelters & refiners
  • Workforce, Form 11-K Savings Plans, Governance, FDA Quality & Environmental Impact › Supply Chain 3TG Conflict Minerals (Form SD) — Known smelters & refiners
  • Consolidated Segment & Financial Statement Context (Database) › DB Segment — Biopharma Segment Revenues ($M) › DB Revenue Type — Alliance Revenues ($M)

Dữ liệu cập nhật 2026-11-02.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Oncology — Brand Revenues (Ibrance, Padcev, Xtandi, Seagen ADC Franchise & Targeted Therapies)

Specialty Care, Global Hospital & Biosimilars, Alliance/Royalty & CDMO

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Pfizer

See a number that looks wrong?